
Kiora Pharmaceuticals (NASDAQ:KPRX) enrols the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial Defect (PCED).
The Phase 2 clinical trial is designed as a single-arm, open label ten patient (up to 20 eyes) study, evaluating subjects 28 days after receiving KIO-201 six times daily.